PRDM16/MEL1 Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 0.2 mg/ml

PRDM16/MEL1 Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 17 amino acids near the carboxy terminus of human PRDM16.

  Source: Synthetic

  (Accession #: CAH71530)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: PRDM16
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-77096.
  
  For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin.
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for PRDM16/MEL1 Antibody Blocking Peptide

• MDS1/EVI1-like gene 1
• MEL1
• MEL1KIAA1675PFM13MGC166915
• PFM13
• PR domain containing 16
• PR domain zinc finger protein 16
• PR domain-containing protein 16
• PRDM16
• Transcription factor MEL1

Background

The reciprocal translocation t(1;3)(p36;q21) occurs in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This gene is located near the 1p36.3 breakpoint and has been shown to be specifically expressed in the t(1:3)(p36,q21)-positive MDS/AML. The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal PR domain. The translocation results in the overexpression of a truncated version of this protein that lacks the PR domain, which may play an important role in the pathogenesis of MDS and AML. Alternatively spliced transcript variants encoding distinct isoforms have been reported.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: PRDM16